Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Vet Comp Oncol ; 21(4): 685-699, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37635372

ABSTRACT

Canine meningiomas are currently graded using the human grading system. Recently published guidelines have adapted the human grading system for use in dogs. The goal of this study was to validate the new guidelines for canine meningiomas. To evaluate the inter-observer agreement, 5 veterinary surgical pathologists graded 158 canine meningiomas following the human grading system alone or with the new guidelines. The inter-observer agreement for histologic grade and each of the grading criteria (mitotic grade, invasion, spontaneous necrosis, macronucleoli, small cells, hypercellularity, pattern loss and anaplasia) was evaluated using the Fleiss kappa index. The diagnostic accuracy (sensitivity and specificity) was assessed by comparing the diagnoses obtained with the 2 grading systems with a consensus grade (considered the reference classification). The consensus histologic grade was obtained by agreement between 4 experienced veterinary neuropathologists following the guidelines. Compared with the human grading alone, the canine-specific guidelines increased the inter-observer agreement for: histologic grade (κ = 0.52); invasion (κ = 0.67); necrosis (κ = 0.62); small cells (κ = 0.36); pattern loss (κ = 0.49) and anaplasia (κ = 0.55). Mitotic grade agreement remained substantial (κ = 0.63). The guidelines improved the sensitivity in identifying grade 1 (95.6%) and the specificity in identifying grade 2 (96.2%) meningiomas. In conclusion, the new grading guidelines for canine meningiomas are associated with an overall improvement in the inter-observer agreement and higher diagnostic accuracy in diagnosing grade 1 and grade 2 meningiomas.


Subject(s)
Dog Diseases , Meningeal Neoplasms , Meningioma , Humans , Dogs , Animals , Meningioma/diagnosis , Meningioma/veterinary , Meningioma/pathology , Anaplasia/veterinary , Dog Diseases/diagnosis , Meningeal Neoplasms/diagnosis , Meningeal Neoplasms/veterinary , Meningeal Neoplasms/pathology , Necrosis/veterinary , Reference Standards , Neoplasm Grading
2.
Front Oncol ; 12: 923679, 2022.
Article in English | MEDLINE | ID: mdl-36419904

ABSTRACT

Glioblastoma is considered the most common malignant primary tumor of central nervous system. In spite of the current standard and multimodal treatment, the prognosis of glioblastoma is poor. For this reason, new therapeutic approaches need to be developed to improve the survival time of the glioblastoma patient. In this study, we performed a preclinical experiment to evaluate therapeutic efficacy of 166Ho microparticle suspension administered by microbrachytherapy on a minipig glioblastoma model. Twelve minipigs were divided in 3 groups. Minipigs had injections into the tumor, containing microparticle suspensions of either 166Ho (group 1; n = 6) or 165Ho (group 2; n = 3) and control group (group 3; n = 3). The survival time from treatment to euthanasia was 66 days with a good state of health of all minipigs in group 1. The median survival time from treatment to tumor related death were 8.6 and 7.3 days in groups 2 and control, respectively. Statistically, the prolonged life of group 1 was significantly different from the two other groups (p < 0.01), and no significant difference was observed between group 2 and control (p=0.09). Our trial on the therapeutic effect of the 166Ho microparticle demonstrated an excellent efficacy in tumor control. The histological and immunohistochemical analysis showed that the efficacy was related to a severe 166Ho induced necrosis combined with an immune response due to the presence of the radioactive microparticles inside the tumors. The absence of reflux following the injections confirms the safety of the injection device.

3.
Vet Comp Oncol ; 20(2): 509-520, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35066998

ABSTRACT

The human grading system is currently applied to canine meningioma, although it has not been validated in dogs. The present study focused on standardising the human grading system applied to canine meningioma. Four veterinary neuropathologists graded 186 canine meningiomas as follows: Grade I tumour, with <4 mitoses/2.37 mm2 ; Grade II tumour, with ≥4 mitoses/2.37 mm2 , brain invasion or at least three of the following criteria: sheeting architecture, hypercellularity, small cells, macronucleoli, necrosis; Grade III tumour, with ≥20 mitoses/2.37 mm2 or anaplasia. Slides with grading disagreement were reviewed to define a consensus diagnosis and to assess reproducible criteria. Concordance between histologic grade and the consensus diagnosis, as well as intra- and inter-observer agreements for each criterion, were statistically analysed. Concordance between histologic grade and consensus diagnosis ranged from 59% to 100%, with lower concordance for Grade I and II tumours. The lowest inter-observer agreement was recorded for macronucleoli, small cells, hypercellularity and sheeting architecture. Tumour invasion and necrosis displayed fair agreement, while moderate agreement was reached for mitotic grade and anaplasia. The following recommendations were issued to improve the reproducibility of canine meningioma grading: (1) Assess mitotic grade in consecutive HPFs within the most mitotically active area; (2) Define invasion as neoplastic protrusions within central nervous tissue without pial lining; (3) Report spontaneous necrosis; (4) Report prominent nucleoli when visible at ×100; (5) Report pattern loss when visible at ×100 in >50% of the tumour; (6) Report necrosis, small cells, hypercellularity and macronucleoli, even when focal; (7) Report anaplasia if multifocal.


Subject(s)
Dog Diseases , Meningeal Neoplasms , Meningioma , Anaplasia/veterinary , Animals , Dog Diseases/diagnosis , Dog Diseases/pathology , Dogs , Humans , Meningeal Neoplasms/diagnosis , Meningeal Neoplasms/pathology , Meningeal Neoplasms/veterinary , Meningioma/diagnosis , Meningioma/pathology , Meningioma/veterinary , Necrosis/veterinary , Neoplasm Grading , Observer Variation , Reproducibility of Results
4.
Vet Pathol ; 57(5): 599-607, 2020 09.
Article in English | MEDLINE | ID: mdl-32783525

ABSTRACT

Canine cutaneous histiocytoma (CCH) is a noninfectious tumor that spontaneously regresses. It is suggested that this regression is due to tumor cell maturation, which is responsible for CD8 lymphocyte activation and tumor cell destruction. Nevertheless, the possible role of the immune microenvironment in tumor regression has not been investigated to date. The aim of this study was to investigate the expression of CD208 and FoxP3 as markers of dendritic cells and regulatory T lymphocytes, respectively, and tumor cell expression of CD206 as a marker of Langerhans cell activation, and relate these parameters to the different phases of CCH and to intratumoral T cell infiltration. Formalin-fixed, paraffin-embedded samples from 31 CCH were evaluated. In each case, the mitotic count and regression phase were recorded. Within the tumor, a quantitative evaluation of immunolabeled CD208+ cells, FoxP3+ cells, and CD3+ lymphocytes was performed, as well as the CD206+ tumor cell location. Intratumoral CD208+ cells correlated with CD3+ lymphocytic infiltration. The possible role of dendritic cells in tumor regression was not confirmed since CD208 seemed to be a nonspecific marker for canine dendritic cells. FoxP3+ lymphocyte density was not correlated with any parameter. Neoplastic Langerhans cells presented progressive CD206 expression, from the bottom of the tumor to the epidermis, which correlated with the tumor regression phase and with intratumoral T lymphocyte infiltration. In conclusion, we confirmed a CD206 phenotype change in tumor cells in a spatial group-related pattern, supporting the hypothesis that tumoral Langerhans cells acquire a mature phenotype with tumor regression.


Subject(s)
Biomarkers/metabolism , Dog Diseases/pathology , Histiocytoma, Benign Fibrous/veterinary , Skin Neoplasms/veterinary , Animals , Dogs , Forkhead Transcription Factors/metabolism , Histiocytoma, Benign Fibrous/pathology , Immunohistochemistry/veterinary , Langerhans Cells/pathology , Lectins, C-Type/metabolism , Lymphocytes, Tumor-Infiltrating/pathology , Lysosomal-Associated Membrane Protein 3/metabolism , Mannose Receptor , Mannose-Binding Lectins/metabolism , Phenotype , Receptors, Cell Surface/metabolism , Skin/pathology , Skin Neoplasms/pathology , T-Lymphocytes, Regulatory/pathology
5.
PLoS One ; 15(6): e0234772, 2020.
Article in English | MEDLINE | ID: mdl-32555746

ABSTRACT

Glioblastoma is the most aggressive primary brain tumor leading to death in most of patients. It comprises almost 50-55% of all gliomas with an incidence rate of 2-3 per 100,000. Despite its rarity, overall mortality of glioblastoma is comparable to the most frequent tumors. The current standard treatment combines surgical resection, radiotherapy and chemotherapy with temozolomide. In spite of this aggressive multimodality protocol, prognosis of glioblastoma is poor and the median survival remains about 12-14.5 months. In this regard, new therapeutic approaches should be developed to improve the life quality and survival time of the patient after the initial diagnosis. Before switching to clinical trials in humans, all innovative therapeutic methods must be studied first on a relevant animal model in preclinical settings. In this regard, we validated the feasibility of intratumoral delivery of a holmium (Ho) microparticle suspension to an induced U87 glioblastoma model. Among the different radioactive beta emitters, 166Ho emits high-energy ß(-) radiation and low-energy γ radiation. ß(-) radiation is an effective means for tumor destruction and γ rays are well suited for imaging (SPECT) and consequent dosimetry. In addition, the paramagnetic Ho nucleus is a good asset to perform MRI imaging. In this study, five minipigs, implanted with our glioblastoma model were used to test the injectability of 165Ho (stable) using a bespoke injector and needle. The suspension was produced in the form of Ho microparticles and injected inside the tumor by a technique known as microbrachytherapy using a stereotactic system. At the end of this trial, it was found that the 165Ho suspension can be injected successfully inside the tumor with absence or minimal traces of Ho reflux after the injections. This injection technique and the use of the 165Ho suspension needs to be further assessed with radioactive 166Ho in future studies.


Subject(s)
Brain Neoplasms/radiotherapy , Glioblastoma/radiotherapy , Holmium/chemistry , Radiopharmaceuticals/administration & dosage , Siloxanes/chemistry , Animals , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/pathology , Cell Line, Tumor , Disease Models, Animal , Feasibility Studies , Female , Glioblastoma/diagnostic imaging , Glioblastoma/pathology , Humans , Male , Radiopharmaceuticals/chemistry , Radiopharmaceuticals/metabolism , Swine , Swine, Miniature , Tomography, Emission-Computed, Single-Photon , Transplantation, Heterologous
6.
Vet Pathol ; 56(3): 342-349, 2019 05.
Article in English | MEDLINE | ID: mdl-30663521

ABSTRACT

In routine diagnostic activity, pathologists may be confronted with nervous system tumors. The lack of clinical information, economic restrictions for additional testing, and the lack of expertise in neuropathology may render the diagnosis challenging. The goals of this study were to assess the agreement in diagnosing nervous system tumors in domestic carnivores among 4 board-certified surgical pathologists without particular expertise in neuropathology and a neuropathologist expert, and to investigate the utility of special stains frequently used in routine diagnostic laboratories. Forty-six tumors (7 cats, 38 dogs, and 1 unknown carnivore) were retrieved and 1 hematoxylin and eosin-stained slide per tumor was selected. Diagnoses (tumor type and subtype) were formulated based on histological features and available clinical information. Confidence in the diagnosis was also scored. Subsequently, a panel of histochemical and immunohistochemical stains (Gordon Sweet silver stain and immunohistochemistry for AE1/AE3, vimentin, glial fibrillary acid protein, S100, neuron-specific enolase and neurofilament) was evaluated by the pathologists, who either confirmed or changed their original diagnoses. Intraobserver and interobserver agreement and confidence in relation to diagnosis before and after analysis of special stains were assessed. The use of special stains increased the complete agreement among surgical pathologists, with regard to tumor type, from 63% to 74%. Cases with a high confidence score had a higher interobserver agreement than cases with a low confidence score. These results suggest that pathologists without expertise in neuropathology agree in the diagnosis of most nervous system tumors, and special stains available in most laboratories only slightly increase this agreement.


Subject(s)
Cat Diseases/diagnosis , Dog Diseases/diagnosis , Nervous System Neoplasms/veterinary , Animals , Cat Diseases/pathology , Cats , Coloring Agents , Dog Diseases/pathology , Dogs , Female , Male , Nervous System/pathology , Nervous System Neoplasms/diagnosis , Nervous System Neoplasms/pathology , Observer Variation
7.
Vet Pathol ; 55(4): 597, 2018 07.
Article in English | MEDLINE | ID: mdl-29890926

ABSTRACT

The article "CD204-Expressing Tumor-Associated Macrophages Are Associated With Malignant, High-Grade, and Hormone Receptor-Negative Canine Mammary Gland Tumors" does not provide evidence that CD204 is a marker for M2 macrophages.


Subject(s)
Macrophages , Mammary Neoplasms, Animal , Scavenger Receptors, Class A , Animals , Prognosis
8.
J Neurosci Methods ; 282: 61-68, 2017 Apr 15.
Article in English | MEDLINE | ID: mdl-28284687

ABSTRACT

BACKGROUND: Glioblastoma is the most common and deadliest primary brain tumor for humans. Despite many efforts toward the improvement of therapeutic methods, prognosis is poor and the disease remains incurable with a median survival of 12-14.5 months after an optimal treatment. To develop novel treatment modalities for this fatal disease, new devices must be tested on an ideal animal model before performing clinical trials in humans. NEW METHOD: A new model of induced glioblastoma in Yucatan minipigs was developed. Nine immunosuppressed minipigs were implanted with the U87 human glioblastoma cell line in both the left and right hemispheres. Computed tomography (CT) acquisitions were performed once a week to monitor tumor growth. RESULTS: Among the 9 implanted animals, 8 minipigs showed significant macroscopic tumors on CT acquisitions. Histological examination of the brain after euthanasia confirmed the CT imaging findings with the presence of an undifferentiated glioma. COMPARISON WITH EXISTING METHOD: Yucatan minipig, given its brain size and anatomy (gyrencephalic structure) which are comparable to humans, provides a reliable brain tumor model for preclinical studies of different therapeutic METHODS: in realistic conditions. Moreover, the short development time, the lower cyclosporine and caring cost and the compatibility with the size of commercialized stereotactic frames make it an affordable and practical animal model, especially in comparison with large breed pigs. CONCLUSION: This reproducible glioma model could simulate human anatomical conditions in preclinical studies and facilitate the improvement of novel therapeutic devices, designed at the human scale from the outset.


Subject(s)
Brain Neoplasms , Glioblastoma , Neoplasm Transplantation , Swine, Miniature , Animals , Brain/diagnostic imaging , Brain/pathology , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/pathology , Cell Line, Tumor , Cyclosporine/blood , Cyclosporine/pharmacology , Female , Glioblastoma/diagnostic imaging , Glioblastoma/pathology , Humans , Immunosuppressive Agents/blood , Immunosuppressive Agents/pharmacology , Male , Swine , Time Factors , Tomography, X-Ray Computed , Tumor Burden
9.
BMC Vet Res ; 12(1): 275, 2016 Dec 05.
Article in English | MEDLINE | ID: mdl-27919252

ABSTRACT

BACKGROUND: The aim of this study was to describe the prevalence and tissue distribution of neoplasms in Italian ferrets, compared to the epidemiological data previously reported in USA and Japan. METHODS: Signalment and diagnoses of pathological submissions received between 2000 and 2010 were searched; cases with the diagnosis of neoplasm were selected and original sections reviewed to confirm the diagnosis. RESULTS: Nine-hundred and ten samples were retrieved, 690 of which included at least one tumour for a total of 856 tumours. Ferrets with multiple neoplasms were 134 (19.4%). Median age was 5 years, and F/M ratio was 0.99. Endocrine neoplasms were the most common. Other frequent tumours were cutaneous mast cell tumours, sebaceous tumours, and lymphomas. Cutaneous squamous cell carcinomas (SCC) were consistently associated with sebaceous tumours. Twenty-four abdominal spindle cell tumours with an undefined origin were observed. Lymphomas and islet cell tumours had a lower incidence compared with previous extra-European studies. DISCUSSION: Epidemiological information on ferret tumours derives from extra-European countries, mostly USA and Japan. In these countries similar distributions with minor discrepancies have been reported. Compared to previous reports, adrenal tumours were more frequent than pancreatic islet cell neoplasms, and a higher number of mesenchymal neoplasms arising from the adrenal capsule was noted. An unusual association between SCC and sebaceous gland neoplasms and a high number of intrabdominal spindle cell neoplasms with unclear primary origin were noted and grants further investigation. CONCLUSIONS: The tissue distribution of tumours recorded in this study paralleled previous findings in ferrets from USA and Japan. Some differences have been noted in the frequency of lymphoma, adrenal mesenchymal tumours and cutaneous tumours. Some tumours that are among the most common in other species seem to be uncommon in ferrets and are characterized by distinctive predilection sites.


Subject(s)
Ferrets , Neoplasms/veterinary , Animals , Female , Italy , Male , Neoplasms/epidemiology , Prevalence
10.
Immunobiology ; 221(1): 12-22, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26345430

ABSTRACT

Dogs with lymphoma are established as good model for human non-Hodgkin lymphoma studies. Canine cell lines derived from lymphomas may be valuable tools for testing new therapeutic drugs. In this context, we established a canine T-cell line, PER-VAS, from a primary aggressive T-cell lymphoma with large granular morphology. Flow cytometric analysis revealed a stable immunophenotype: PER-VAS cells were positively labelled for CD5, CD45, MHC II and TLR3, and were negative for CD3, CD4 and CD8 expression. Although unstable along the culture process, IL-17 and MMP12 proteins were detectable as late as at passages 280 and 325i.e. respectively 24 and 29 months post isolation. At passage 325, PER-VAS cells maintained the expression of IL-17, CD3, CD56, IFNγ and TNFα mRNAs as shown by RT-PCR analysis. Stable rearrangement of the TCRγ gene has been evidenced by PCR. PER-VAS cells have a high proliferation index with a doubling time of 16.5h and were tumorigenic in Nude mice. Compared to the canine cell lines already reported, PER-VAS cells display an original expression pattern, close to NKT cells, which makes them valuable tools for in vitro comparative research on lymphomas.


Subject(s)
Cell Line/immunology , Gene Expression/immunology , Lymphoma, T-Cell/immunology , RNA, Messenger/immunology , T-Lymphocytes/immunology , Animals , Antigens, CD/genetics , Antigens, CD/immunology , Cell Line/pathology , Dogs , Founder Effect , Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor , Humans , Immunophenotyping , Interferon-gamma/genetics , Interferon-gamma/immunology , Interleukin-17/genetics , Interleukin-17/immunology , Lymphoma, T-Cell/genetics , Lymphoma, T-Cell/pathology , Male , Mice , Mice, Nude , RNA, Messenger/genetics , Receptors, Antigen, T-Cell, gamma-delta/genetics , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocytes/pathology , Toll-Like Receptor 3/genetics , Toll-Like Receptor 3/immunology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology
11.
Can Vet J ; 55(6): 547-50, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24891636

ABSTRACT

A 5-year-old mare was treated for recurrent colic and weight loss by surgical removal of an intraluminal cecal mass. Microscopic examination revealed vascular hamartoma. A 6-month follow-up showed an improvement in the general condition of the mare. Vascular hamartoma should be one of the differential diagnoses for weight loss and colic.


Coliques récurrentes causées par un hamartome vasculaire caecal chez une jument Arabe. Une jument de 5 ans a été traitée pour coliques récurrentes et perte de poids par exérèse chirurgicale d'une masse caecale intraluminale. L'examen microscopique a révélé un hamartome vasculaire. Un suivi de 6 mois a montré une amélioration de l'état général de la jument. L'hamartome vasculaire doit faire partie du diagnostic différentiel de l'amaigrissement et des coliques.(Traduit par les auteurs).


Subject(s)
Cecal Neoplasms/veterinary , Cecum/pathology , Colic/veterinary , Hamartoma/veterinary , Horse Diseases/etiology , Animals , Cecal Neoplasms/complications , Cecal Neoplasms/surgery , Colic/etiology , Female , Hamartoma/complications , Hamartoma/surgery , Horse Diseases/pathology , Horse Diseases/surgery , Horses
12.
Exp Toxicol Pathol ; 65(4): 397-407, 2013 May.
Article in English | MEDLINE | ID: mdl-22405603

ABSTRACT

Repeated exposure to 17-α-methyltestosterone (17MT) and estradiol benzoate (EB) for 28 or 90 days in rats induce similar ovarian atrophy. The objective of the present work was to identify and compare the early effects induced by 17MT and EB on the ovary using molecular and histopathological tools. Female rats were evaluated after 1, 3 or 7 days following an oral exposure by gavage at a daily dose of 600 mg/kg/day for 17MT and 5 mg/kg/day for EB. All animals were found to be acyclic after 3 or 7 days of treatment with 17MT and EB. Histopathological changes were present in the ovary, uterus, vagina and mammary gland after both treatments. Ovarian atrophy known as the long term effect of 17MT and EB was not yet detected after 7 days of treatment. But non regressive corpora lutea and cystic follicles were identically observed in the ovary of 17MT and EB treated females. Both compounds induced a decrease of LH transcripts together with an increase of plasma progesterone and prolactin levels. Differences in the profile of regulation of the aromatase were noted after 1 and 3 days of treatment in 17MT treated animals (upregulated) when compared to EB treated animals (downregulated). In summary, we have shown that despite the different nature of hormonal activity, EB and 17MT induce very early endocrine perturbation which presents several similarities. Our work indicated that the detection of early key hormonal markers in short term studies can help to predict the adverse long term effects on target tissues.


Subject(s)
Anabolic Agents/toxicity , Contraceptive Agents/toxicity , Estradiol/analogs & derivatives , Methyltestosterone/toxicity , Ovary/drug effects , Animals , Endocrine System/drug effects , Estradiol/toxicity , Estrous Cycle/drug effects , Female , Luteinizing Hormone/blood , Ovary/metabolism , Ovary/pathology , Pituitary Gland/drug effects , Polymerase Chain Reaction , Progesterone/blood , Prolactin/blood , Rats , Rats, Wistar
13.
Environ Sci Pollut Res Int ; 20(5): 3107-14, 2013 May.
Article in English | MEDLINE | ID: mdl-23054794

ABSTRACT

Using varanids as indicators of pollution in African continental wetlands was previously proposed. The present study aimed at understanding experimentally how monitors absorb and accumulate pollutants and how they are affected. The relevance of non-destructive sampling was also evaluated. Savannah monitors (Varanus exanthematicus) were orally exposed during 6 months to a mixture of lead, 4,4'-dichlorodiphenyltrichloroethane (4,4'-DDT) and chlorpyrifos-ethyl (CPF) or to the vehicle only. Proportionally to their mass, exposed monitors received the same dose: 20 then 10 mg lead kg(-1), 2 then 0.5 mg CPF kg(-1) and 4 mg 4,4'-DDT kg(-1). Individuals surviving contamination were euthanized after 4 or 6 months of experiment. Tissues were analysed for lead by atomic absorption spectrophotometry and for DDT and CPF by gas chromatography. Exposed monitors absorbed all three pollutants but only lead (essentially in bone, tail tips and phalanxes) and 4,4'-DDT plus its main metabolites (essentially in fat and liver) accumulated. CPF killed ten individuals. Clear correlations occurred between the total quantity of lead or 4,4'-DDT administered and concentrations in tissues. Tail tips and skin samples are recommended non-destructive indicators for lead and organochlorine pesticides contamination, respectively. This work confirms that monitors can be used as relevant indicators of environmental pollution by lead and organochlorine pesticides. Although varanids withstand heavy lead and DDT contamination, our results suggest that CPF can be lethal at very low doses to the herpetofauna and emphasize the importance of considering all taxa in impact assessment studies, including reptiles.


Subject(s)
DDT/pharmacokinetics , Environmental Exposure , Environmental Pollutants/pharmacokinetics , Lead/pharmacokinetics , Lizards/metabolism , Organothiophosphorus Compounds/pharmacokinetics , Absorption , Animals , Chlorpyrifos , Chromatography, Gas , DDT/toxicity , Environmental Monitoring , Environmental Pollutants/toxicity , Insecticides/pharmacokinetics , Insecticides/toxicity , Lead/toxicity , Organothiophosphorus Compounds/toxicity , Spectrophotometry, Atomic , Tissue Distribution
14.
Avian Pathol ; 38(1): 9-11, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19130351

ABSTRACT

Ocular opacity, associated with reluctance to move and inability to feed properly, was observed in approximately 1% of all newly hatched females from several related flocks of Mulard ducks. A 5-week follow-up study of 10 1-day-old affected females was performed, and they were compared with 10 control animals. Clinical, ocular and ultrasonographic examinations, and a complete necropsy of two animals per group with histological examination of the eye, were performed weekly. A bilateral immature cortical anterior cataract was diagnosed at ocular examination and confirmed by ultrasonography in affected ducks. Dyscoria was occasionally observed in affected animals. Severe cataract, with Morgagnian globules, severe anterior fibre liquefaction and disorganization were observed by photonic microscopy. No retinal or choroidal lesions were observed. No progression or repair of ultrasonographic and microscopic lesions could be detected during the 5 weeks of examination. The female predisposition for the ocular lesions suggests a congenital sex-linked recessive cataract.


Subject(s)
Cataract/veterinary , Ducks , Poultry Diseases/congenital , Animals , Cataract/congenital , Cataract/genetics , Cataract/pathology , Female , Genetic Predisposition to Disease , Poultry Diseases/genetics , Poultry Diseases/pathology
15.
Exp Toxicol Pathol ; 59(6): 385-90, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18222080

ABSTRACT

Histiocytic sarcoma is the most frequent hematopoietic tumor in rats. We report here a histiocytic sarcoma infiltrating the liver, the spleen and the pancreas from a Wistar rat. In the liver, the tumor was associated with oval cell and bile duct hyperplasia. The cells looked like neoplastic histocytic cells described in this species but with some particularities (e.g. lack of multinucleated giant cells). At immunohistochemistry, neoplastic cells in the liver were vimentine positive but lysozyme and CD68 negative. In the kidney, lysozyme-positive cytoplasmic droplets were observed. We describe here an atypical case of histiocytic sarcoma in the rat and we compare the nature of these neoplastic cells to other species.


Subject(s)
Histiocytic Sarcoma/pathology , Liver Neoplasms/pathology , Pancreatic Neoplasms/pathology , Splenic Neoplasms/pathology , Animals , Antigens, CD/biosynthesis , Antigens, Differentiation, Myelomonocytic/biosynthesis , Histiocytic Sarcoma/metabolism , Immunohistochemistry , Kidney/metabolism , Kidney/pathology , Liver Neoplasms/metabolism , Male , Muramidase/biosynthesis , Pancreatic Neoplasms/metabolism , Rats , Rats, Wistar , Splenic Neoplasms/metabolism , Vimentin/biosynthesis
16.
Toxicol Sci ; 100(1): 54-65, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17686919

ABSTRACT

The Organization for Economic Cooperation and Development (OECD) is currently funding the validation of the Hershberger assay as a rapid in vivo means of identifying (anti-) androgens. However, as the assay measures weight changes in the androgen-sensitive tissues of castrated rats, the evaluation of the androgen-stimulated intact weanling as a more ethical model to use in the assay has been requested. As part of the OECD validation exercise two weak antiandrogens, 1,1-dichloro-2,2-bis(4 chlorophenyl)ethane (DDE) and linuron (LIN), were investigated in our laboratory at several dose levels in the testosterone propionate (TP)-stimulated weanling using flutamide (FM) as a positive control. In addition to weight measurements (sex accessory tissues [SATs], epididymides, and testes), histopathological assessment of the seminal vesicles, prostate, and testes was conducted for vehicle control, TP-stimulated, and TP-stimulated animals treated with FM or the top dose level of DDE or LIN. The modulation of a novel prostate protein associated with apoptosis, L-amino acid oxidase (LAO), was evaluated in these same treatment groups. Our gravimetric data (supported by the histopathology data) indicated that the weanling assay can detect SAT and epididymal weight changes induced by the antiandrogens evaluated. Inconsistent and variable data were recorded for the testicular weight and histopathological effects, suggesting that the testis is of little value in the identification of antiandrogens using this model. Three isoforms of LAO were identified, and all were regulated by TP. Modulation of LAO by the antiandrogens indicated that this protein could be a biomarker for endocrine disruption in male rodents.


Subject(s)
Androgen Antagonists/toxicity , Dichlorodiphenyl Dichloroethylene/toxicity , Endocrine Disruptors/toxicity , Flutamide/toxicity , Genitalia, Male/drug effects , Linuron/toxicity , Proteomics , Toxicity Tests/methods , Adrenal Glands/drug effects , Animals , Biomarkers, Pharmacological/metabolism , Body Weight/drug effects , Dose-Response Relationship, Drug , Epididymis/drug effects , Genitalia, Male/metabolism , Genitalia, Male/pathology , Kidney/drug effects , L-Amino Acid Oxidase/metabolism , Liver/drug effects , Male , Organ Size/drug effects , Prostate/drug effects , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Seminal Vesicles/drug effects , Testis/drug effects , Testosterone Propionate/pharmacology , Time Factors , Weaning
17.
Mol Cancer Ther ; 5(9): 2388-97, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16985073

ABSTRACT

Hepatocyte growth factor (HGF) and its tyrosine kinase receptor Met play a pivotal role in the tumor metastatic phenotype and represent attractive therapeutic targets. We investigated the biochemical and biological effects of the tyrosine kinase inhibitor RPI-1 on the human lung cancer cell lines H460 and N592, which express constitutively active Met. RPI-1-treated cells showed down-regulation of Met activation and expression, inhibition of HGF/Met-dependent downstream signaling involving AKT, signal transducers and activators of transcription 3 and paxillin, as well as a reduced expression of the proangiogenic factors vascular endothelial growth factor and basic fibroblast growth factor. Cell growth in soft agar of H460 cells was strongly reduced in the presence of the drug. Furthermore, RPI-1 inhibited both spontaneous and HGF-induced motility/invasiveness of both H460 and human endothelial cells. Targeting of Met signaling by alternative methods (Met small interfering RNA and anti-phosphorylated Met antibody intracellular transfer) produced comparable biochemical and biological effects. Using the spontaneously metastasizing lung carcinoma xenograft H460, daily oral treatment with well-tolerated doses of RPI-1 produced a significant reduction of spontaneous lung metastases (-75%; P < 0.001, compared with control mice). In addition, a significant inhibition of angiogenesis in primary s.c. tumors of treated mice was observed, possibly contributing to limit the development of metastases. The results provide preclinical evidence in support of Met targeting pharmacologic approach as a new option for the control of tumor metastatic dissemination.


Subject(s)
Indoles/pharmacology , Lung Neoplasms/drug therapy , Proto-Oncogene Proteins c-met/antagonists & inhibitors , Angiogenesis Inhibitors/pharmacology , Animals , Carcinoma, Non-Small-Cell Lung/blood supply , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/blood supply , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/pathology , Cell Adhesion/drug effects , Cell Growth Processes/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Female , Hepatocyte Growth Factor/antagonists & inhibitors , Hepatocyte Growth Factor/pharmacology , Humans , Lung Neoplasms/blood supply , Lung Neoplasms/pathology , Mice , Mice, Nude , Neoplasm Metastasis , Phosphorylation/drug effects , Proto-Oncogene Proteins c-met/metabolism , Xenograft Model Antitumor Assays
18.
Biochem Pharmacol ; 72(4): 405-14, 2006 Aug 14.
Article in English | MEDLINE | ID: mdl-16756963

ABSTRACT

Recent evidence indicates that the success of molecular targeted therapies may depend on the identification of drug targets which are essential for the survival of subsets of tumors. RET oncogenes that have been implicated in the development of thyroid carcinomas are emerging as potential therapeutic targets. In the present study, we investigated the efficacy and the cellular bases of antitumor activity of the indolinone Ret tyrosine kinase inhibitor RPI-1 against large established s.c. TT tumor xenograft, a human medullary thyroid carcinoma (MTC) harboring oncogenic MEN-2A-type RET mutation. Oral treatment with RPI-1 caused growth arrest or regression in 81% treated tumors. Following treatment suspension, tumor inhibition was maintained (51%, P<0.05, 100 days) and cures were achieved in 2/11 mice. In treated tumors, Ret was tyrosine dephosphorylated. Moreover, compared to control tumors, a significant increase in apoptotic cells (210%, P<0.0001), loss of cellularity (47%, P<0.0001) and reduction of microvessel density (36%, P<0.0005) were detected. In vivo effects of RPI-1 were reflected in activation of BAD, cleavage of caspases, apoptotic DNA fragmentation and inhibition of VEGF production observed in in vitro RPI-1-treated TT cells. These findings thus indicate that RPI-1 antitumor effect on the MTC was characterized by apoptosis induction and angiogenesis inhibition. The results, consistent with a dependence on RET oncogene activation for maintenance and survival of MEN2A-type MTC, provide further preclinical rationale for a pharmacological RET-targeted intervention in thyroid cancer.


Subject(s)
Apoptosis/drug effects , Carcinoma, Medullary/drug therapy , Indoles/pharmacology , Neovascularization, Pathologic/prevention & control , Thyroid Neoplasms/drug therapy , Administration, Oral , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carcinoma, Medullary/pathology , Cell Line, Tumor , Female , Flow Cytometry , Humans , Indoles/administration & dosage , Indoles/therapeutic use , Mice , Mice, Nude , Mutation , NIH 3T3 Cells , Phosphorylation/drug effects , Proto-Oncogene Proteins c-ret/antagonists & inhibitors , Proto-Oncogene Proteins c-ret/genetics , Proto-Oncogene Proteins c-ret/metabolism , Thyroid Neoplasms/pathology , Vascular Endothelial Growth Factor A/metabolism , Xenograft Model Antitumor Assays
19.
Am J Pathol ; 168(4): 1262-75, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16565500

ABSTRACT

In rare families RET tyrosine kinase receptor substitutions located in exon 10 (especially at positions 609, 618, and 620) can concomitantly cause the MEN 2A (multiple endocrine neoplasia type 2A) or FMTC (familial medullary thyroid carcinoma) cancer syndromes, and Hirschsprung's disease (HSCR). No animal model mimicking the co-existence of the MEN 2 pathology and HSCR is available, and the association of these activating mutations with a developmental defect still represents an unresolved problem. The aim of this work was to investigate the significance of the RET(C620R) substitution in the pathogenesis of both gain- and loss-of-function RET-associated diseases. We report the generation of a line of mice carrying the C620R mutation in the Ret gene. Although Ret(C620R) homozygotes display severe defects in kidney organogenesis and enteric nervous system development leading to perinatal lethality. Ret(C620R) heterozygotes recapitulate features characteristic of HSCR including hypoganglionosis of the gastrointestinal tract. Surprisingly, heterozygotes do not show any defects in the thyroid that might be attributable to a gain-of-function mutation. The Ret(C620R) allele is responsible for HSCR and affects the development of kidneys and the enteric nervous system (ENS). These mice represent an interesting model for studying new therapeutic approaches for the treatment of HSCR disease.


Subject(s)
Gastrointestinal Tract/embryology , Hirschsprung Disease/pathology , Kidney/embryology , Proto-Oncogene Proteins c-ret/genetics , Amino Acid Substitution , Animals , Cells, Cultured , Disease Models, Animal , Enteric Nervous System/abnormalities , Enteric Nervous System/embryology , Enteric Nervous System/metabolism , Female , Ganglia, Spinal/metabolism , Ganglia, Spinal/pathology , Gastrointestinal Tract/innervation , Gastrointestinal Tract/metabolism , Hirschsprung Disease/embryology , Hirschsprung Disease/genetics , Kidney/pathology , Male , Mice , Mice, Mutant Strains , Proto-Oncogene Proteins c-ret/metabolism , Thyroid Gland/abnormalities , Thyroid Gland/embryology , Thyroid Gland/metabolism
20.
Cancer Res ; 65(14): 6388-93, 2005 Jul 15.
Article in English | MEDLINE | ID: mdl-16024642

ABSTRACT

CpG-oligodeoxynucleotides (CpG-ODN) exhibit potent immunostimulatory activity by binding with Toll-like receptor 9 (TLR9). Based on the finding that TLR9 is highly expressed and functional in pancreatic tissue, we evaluated the antitumor effects of chemotherapy combined with CpG-ODNs in the orthotopic mouse model of a human pancreatic tumor xenograft. Chemotherapy consisted of the maximum tolerated dose of gemcitabine (i.v., 100 mg/kg, q3dx4). CpG-ODNs were delivered (i.p., 20 microg/mouse), weekly, after the end of chemotherapy. CpG-ODNs alone had little effect on tumor growth, whereas gemcitabine alone significantly delayed the median time of disease onset (palpable i.p. tumor) and of bulky disease development (extensive peritoneal tumor burden), but did not enhance survival time. When the gemcitabine regimen was followed by administration of the immunostimulator, development of bulky disease was delayed, survival time was significantly improved (median survival time, 106 days; P < 0.02 versus gemcitabine-treated mice). Autoptic examination showed that tumor spread in the peritoneal cavity was reduced to a greater extent than with gemcitabine alone. All treatment regimens were well-tolerated. The use of nude mice excluded a T cell-mediated immune response, whereas the high pancreatic expression of TLR9 might have contributed to the tumor response. The clear improvement of survival observed in an orthotopic murine model of human pancreatic cancer by the combined use of CpG-ODNs with chemotherapy suggests the promise of this therapeutic regimen in the clinical setting.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Pancreatic Neoplasms/drug therapy , Animals , Combined Modality Therapy , CpG Islands/genetics , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/deficiency , DNA-Binding Proteins/genetics , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Drug Synergism , Female , Humans , Immunotherapy , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Nude , Oligonucleotides/administration & dosage , Oligonucleotides/genetics , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/metabolism , Receptors, Cell Surface/biosynthesis , Receptors, Cell Surface/deficiency , Receptors, Cell Surface/genetics , Toll-Like Receptor 9 , Tumor Cells, Cultured , Xenograft Model Antitumor Assays , Gemcitabine
SELECTION OF CITATIONS
SEARCH DETAIL
...